MED²ICIN Symposium 2023 at the University in Frankfurt

Seven Fraunhofer institutes have joined forces in an interdisciplinary research network as part of MED²ICIN to create the conditions for more effective prevention, diagnosis, therapy and care with the help of technology-driven innovations. In a digital patient model, patient data are compared with each other and matched with parameters from population studies and data of specific disease patterns.

more info
© iStock.com/1223190133
Man elegant suit uses futuristic technology. Concept: immersive technology, futuristic medicine, congresses and meetings

The Fraunhofer Center for Digital Diagnostics

Fraunhofer bundles competencies for the targeted development of digital diagnostics solutions. In the Potsdam model region, new solutions and fields of application for digital diagnostics are being researched and developed in order to effectively support patient care and realize value-added potential in the region.

more info

© iStock.com/1223190133

© Ekaterina_1525 - stock.adobe.com / Fraunhofer IZI / Alernon77 - stock.adobe.com / CoreDESIGN - stock.adobe.com / Fraunhofer IZI

Fraunhofer develops automated production technologies for mRNA-based drugs

Coordinated by the Fraunhofer Institute for Cell Therapy and Immunology IZI, seven Fraunhofer institutes are working on the development of automated production technologies for mRNA-based drugs. RNAuto is a Fraunhofer lighthouse project that will receive €8 million in funding from the Fraunhofer-Gesellschaft over the next four years.

more info

© Ekaterina_1525 - stock.adobe.com / Fraunhofer IZI / Alernon77 - stock.adobe.com / CoreDESIGN - stock.adobe.com / Fraunhofer IZI

© links: Fraunhofer IST, Falko Oldenburg | rechts: Fraunhofer IST, Paul Kurze

Plasma treatment during 3D printing improves acceptance of implants

In the High-Performance Center Medical and Pharmaceutical Engineering, researchers at the Fraunhofer Institute for Surface Engineering and Thin Films IST have succeeded in integrating a plasma source into a 3D printer, thereby enabling the surface to be modified. The aim is to treat the scaffolds with plasma during the actual printing process in order to produce the desired properties.

more info

© links: Fraunhofer IST, Falko Oldenburg | rechts: Fraunhofer IST, Paul Kurze

Fraunhofer Health

Health research at Fraunhofer addresses the four key areas of medical science — drugs, diagnostics, devices and data, or 4D for short. Many innovations emerge at the interface between medical science, natural science, computer science and engineering. With its emphasis on transdisciplinary research, the Fraunhofer-Gesellschaft offers the perfect environment for close collaboration on health research and the development of cost-intelligent precision medicine for the benefit of patients.

News

 

© Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Designer immune cells for drug discovery, potency and safety testing

To prevent testing on animals and create even more precise ways of testing therapeutics, the pharmaceutical industry is increasingly turning to human immune cells. However, the availability of cells like these has been limited to date. Now, Fraunhofer researchers have succeeded in scaling the production of customized immune cells from laboratory up to industrial level.

Press release
 

Fraunhofer Institute for Biomedical Engineering IBMT

Development and validation of a software platform for the prevention, detection and analysis of cyberattacks in the healthcare sector

In the EU project »AI4HealthSec«, an international team of researchers aims to provide operators of health information infrastructures with innovative software tools to improve the detection and analysis of cyberattacks and threats and thus, to increase the security of health information infrastructures. For this purpose, the project will develop and validate the so-called AI4HealthSec platform. The Fraunhofer Institute for Biomedical Engineering IBMT is contributing its many years of expertise in the development of innovative health information systems and their validation to the project. It provides three of its systems as examples to test the AI4HealthSec platform.

Press Release
 

© Fraunhofer IZI

Fraunhofer Institute for Cell Therapy and Immunology IZI

Fraunhofer IZI research project nominated for "HUGO JUNKERS PRIZE for Research and Innovation from Saxony-Anhalt"

The Fraunhofer Institute for Cell Therapy and Immunology IZI conducts research on neurodegenerative and inflammatory diseases at its Halle (Saale) site. With their approach of using endogenous retroviruses as target structures for new therapies against neurological diseases, the scientists qualified for the finals of this year's HUGO JUNKERS AWARD in the category "Most Innovative Basic Research Projects".

News
 

© Fraunhofer IBMT

Fraunhofer Institute for Biomedical Engineering IBMT

Human-machine interface stops muscle tremors

Scientists at the Fraunhofer Institute for Biomedical Engineering IBMT have been working with international partners to develop a technology platform to help relieve the symptoms of muscle tremors. Tiny biocompatible electrodes in the muscles, combined with external electrodes and controllers, form an intelligent network of sensors and actuators to detect muscle signals and provide electrical stimuli as needed. Together with exoskeletons, the technology could also help people with spinal cord injuries.

Press Release
 

© Photo by WikiImages on Pixabay

Fraunhofer Institute for Cell Therapy and Immunology IZI

Fraunhofer IZI contributes expertise to Germany's largest collaborative project on mosquito research

The interdisciplinary joint project CuliFo combines field and laboratory research on mosquitoes, Latin Culicidae, in Germany. Climatic changes increase the risk that exotic mosquitoes occur in our latitudes.

News
 

© Fraunhofer IZI-BB

Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses IZI-BB

switchSENSE technology for quantitative determination of virus-receptor binding

Press Release (German only)
 

© Fraunhofer MEVIS

Fraunhofer Institute for Digital Medicine MEVIS

A complete package for minimally invasive tumor therapy

License agreement and joint development: Fraunhofer MEVIS commences cooperation with Israeli partner for worldwide use of innovative software technology in ultrasound-aided tumor ablation

Press release
 

© Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Bioresorbable membrane for healing internal and external wounds

Fraunhofer researchers have succeeded in using the bioresorbable silica gel Renacer® to produce an electrospun membrane that is neither cytotoxic to cells nor genotoxic. This model mimics fibrous structures found in connective tissue and is therefore particularly suitable for regenerative applications, such as for improved wound healing.

Press release
 

© WILDDESIGN GmbH, Gelsenkirchen

Fraunhofer Institute for Biomedical Engineering IBMT

A new generation of microimplants

They are barely the size of a thumbnail, able to communicate with each other and respond to each other, and designed to make life easier for people with functional limitations. We are talking about a new generation of interactive microimplants developed by the innovation cluster INTAKT, which is funded by the German Federal Ministry of Education and Research (BMBF) and coordinated by the Fraunhofer Institute for Biomedical Engineering IBMT. These miniature assistants can act as a stimulus in cases of tinnitus or digestive tract disorders or help a person’s hand to regain the ability to grip.

Press release
 

© Mike Auerbach

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Better therapy for lung diseases: Pulmonologists honor outstanding poster works

Die Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) hat im Rahmen ihres Kongresses in Düsseldorf jetzt die besten wissenschaftlichen Poster ausgezeichnet. Den mit 2.000 Euro dotierten ersten Platz belegt Nataliia Artysh (29 Jahre) vom Fraunhofer Institut für Toxikologie und Experimentelle Medizin in Hannover. 

Press Release of the German Respiratory Society (German only)
 

© Manfred Neubauer

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Pandemic research at the Penzberg site - scientists provide insights into first projects

Together with its partners Roche Diagnostics GmbH and Ludwig-Maximilians-University, the Fraunhofer ITMP has set itself the goal of identifying and characterizing pandemic pathogens, developing new diagnostics and therapies, and better understanding the role of the immune system in infectious diseases. Last but not least, this will help to find ways to better protect against possible new pandemics in the future.

Press Release (German only)
 

© Fraunhofer FEP

DNA, RNA and peptides as storage media

Within the project »BIOSYNTH – modular high-throughput microplatform for future synthetic biology mass data storage«, funded by the Fraunhofer-Gesellschaft in an internal program, an innovative microchip platform for efficient cell-free and digitally controllable biosynthesis will be developed. 

zum Projekt
 

© Fraunhofer IGD

Fraunhofer Lighthouse project MED²ICINE

MED²ICIN – Digital patient model as a basis for personalised and cost-optimised treatment

Further Information
 

Fraunhofer Institute for Cell Therapy and Immunology IZI

GLP test facility of the Fraunhofer IZI certified for test category 2 since January 2023

The GLP test facility of the Fraunhofer Institute for Cell Therapy and Immunology has been certified for testing category 9 "Safety testing of ATMPs - immunotoxicity / immunogenicity, biodistribution and tumorigenicity in vitro / in vivo" since 2009. Since January 2023, the testing category 2 "Toxicity studies" is now also part of the portfolio.

News
 

© iStock

Archive

News Archive

Further notifications from our member institutes

Archive